XML 73 R49.htm IDEA: XBRL DOCUMENT  v2.3.0.11
Collaborative Arrangements (Details) (USD $)
 3 Months Ended 6 Months Ended 1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended 1 Months Ended 3 Months Ended 6 Months Ended 1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended 1 Months Ended 3 Months Ended 6 Months Ended
Jun. 30, 2011
Jun. 30, 2010
Jun. 30, 2011
Jun. 30, 2010
Dec. 31, 2010
Sep. 30, 2009
Janssen Pharmaceutical, N.V.
Jul. 31, 2006
Janssen Pharmaceutical, N.V.
Jun. 30, 2006
Janssen Pharmaceutical, N.V.
Jun. 30, 2011
Janssen Pharmaceutical, N.V.
Mar. 31, 2011
Janssen Pharmaceutical, N.V.
Jun. 30, 2010
Janssen Pharmaceutical, N.V.
Mar. 31, 2010
Janssen Pharmaceutical, N.V.
Sep. 30, 2009
Janssen Pharmaceutical, N.V.
Jun. 30, 2011
Janssen Pharmaceutical, N.V.
Jun. 30, 2010
Janssen Pharmaceutical, N.V.
Dec. 31, 2007
Janssen Pharmaceutical, N.V.
Jul. 31, 2009
Mitsubishi Tanabe Pharma Corporation
Jun. 30, 2011
Mitsubishi Tanabe Pharma Corporation
Jun. 30, 2010
Mitsubishi Tanabe Pharma Corporation
Sep. 30, 2009
Mitsubishi Tanabe Pharma Corporation
Jun. 30, 2011
Mitsubishi Tanabe Pharma Corporation
Jun. 30, 2010
Mitsubishi Tanabe Pharma Corporation
Apr. 30, 2011
Cystic Fibrosis Foundation Therapeutics Incorporated
Jun. 30, 2011
Cystic Fibrosis Foundation Therapeutics Incorporated
Jun. 30, 2011
Cystic Fibrosis Foundation Therapeutics Incorporated
Dec. 31, 2006
Cystic Fibrosis Foundation Therapeutics Incorporated
Jun. 30, 2011
Alios BioPharma, Inc
Jun. 30, 2011
Alios BioPharma, Inc
Jun. 30, 2011
Alios BioPharma, Inc
Jun. 13, 2011
Alios BioPharma, Inc
Schedule of Collaborative Arrangements                                                            
Drug development costs to be paid by collaborator (as a percent)               50.00%           50.00%                                
Up-front license payment             $ 165,000,000                                              
Decrease in revenue recognition per quarter due to change in estimate regarding period of performance under Janssen collaboration agreement                       1,400,000 1,100,000     2,600,000                            
Deferred revenue related to up-front license payment                 62,100,000         62,100,000       31,900,000     31,900,000                  
Total contingent milestone payments earned                           150,000,000                                
Milestone payment earned in the first quarter of 2011 in connection with the EMA acceptance of the MAA for telaprevir                   50,000,000                                        
Maximum value of unearned contingent milestone payments under agreement                           200,000,000                                
Revenue to be earned upon achievement of the approval milestone                           50,000,000                                
Revenue to be earned upon achievement of the launch milestones                           150,000,000                                
Number of financial transactions entered into related to milestones           2                                                
Value of milestones related to the September 2009 Financial Transactions           250,000,000                                                
Tiered royalty average range, as a percentage of net sales in the Janssen territories               mid-20% range                                            
Notice period required to terminate without cause prior to receipt of marketing approval (in months)               6                                            
Notice period required to terminate without cause after receipt of marketing approval (in years)               1                                            
License fee paid upon amendment of agreement                                 105,000,000                          
Contingent milestone payment, low end of range                                 15,000,000                          
Contingent milestone payment, high end of range                                 65,000,000                          
Notice period required to terminate without cause (in days)                                       60                    
Collaborative revenues recognized                                                            
Amortized portion of up-front payment                 3,107,000   3,107,000     0 6,214,000     9,558,000 9,558,000   19,116,000 19,116,000                
Development milestone revenues                           50,000,000       182,000     1,394,000                  
Net reimbursement (payment) for telaprevir development costs                 (3,108,000)   3,501,000     (4,253,000) 5,907,000                              
Reimbursement for manufacturing services                 9,059,000   5,274,000     13,213,000 6,225,000     5,133,000 2,478,000   5,848,000 2,478,000                
Total collaborative revenues attributable to the collaboration 29,879,000 24,360,000 97,480,000 40,382,000         9,058,000   11,882,000     65,174,000 18,346,000     14,873,000 12,036,000   26,358,000 21,594,000   5,900,000            
Number of amendments entered into for partial funding                                                   2        
Collaborative funding                                             75,000,000              
Number of years over which funding will be made (in years)                                             5              
Milestone payment received                                                   1,500,000        
Collaborative revenues 29,879,000 24,360,000 97,480,000 40,382,000         9,058,000   11,882,000     65,174,000 18,346,000     14,873,000 12,036,000   26,358,000 21,594,000   5,900,000            
Number of commercial milestone payments for achievement of certain sales levels for potentiator compound such as VX-770                                                 2          
Number of commercial milestone payments for achievement of certain sales levels for corrector compound such as VX-809 or VX-661                                                 2          
Number of nucleotide analogues discovered by acquiree                                                     2      
Research and development milestone payments, maximum                                                     715,000,000      
Commercial milestone payments, maximum                                                     750,000,000      
Notice period for termination of contract due to technical failure (in days)                                                     30      
Notice period for termination of contract after completion of clinical trials (in days)                                                     60      
Latest expiration period for royalty obligation after first commercial sale in country unless contract is terminated earlier (in years)                                                     10      
Discount rate for contingent milestones and royalty payments for development milestones, low end of range (as a percent)                                                           3.60%
Discount rate for contingent milestones and royalty payments for development milestones, high end of range (as a percent)                                                           6.50%
Discount rate for contingent milestones and royalty payments for commercial milestones and royalties (as a percent)                                                           9.40%
Up-front payment                                                           60,000,000
Fair value of contingent milestone and royalty payments                                                           197,720,000
Total Consideration                                                           257,720,000
Discount rate for intangible assets acquired (as a percent)                                                           9.50%
Intangible assets                                                           250,600,000
Goodwill                                                           7,399,000
Deferred tax liability Net (260,448,000) [1]   (260,448,000) [1]   (160,278,000)                                           (100,076,000) (100,076,000) (100,076,000) (90,840,000)
Net other assets (liabilities)                                                           (279,000)
Net assets attributable to noncontrolling interests (Alios)                                                           166,880,000
Noncontrolling Interest (Alios)                                                            
Number of lines on balance sheet where noncontrolling interest is reported                                                     2 2 2  
Loss of noncontrolling interest (Alios) before provision for income taxes                                                       (801,000)    
Income tax Provision (Alios) 24,448,000   24,448,000                                                 (24,448,000) (24,448,000)  
Net loss attributable to noncontrolling interest (Alios) (25,249,000) 0 (25,249,000) 0                                               (25,249,000)    
Restricted cash and cash equivalents (Alios) 63,098,000 [1]   63,098,000 [1]                                               63,098,000 63,098,000 63,098,000 4,575,000
Prepaid expenses and other current assets 21,897,000 [1]   21,897,000 [1]   13,099,000                                           120,000 120,000 120,000 69,000
Property and equipment, net 84,203,000 [1]   84,203,000 [1]   72,333,000                                           1,012,000 1,012,000 1,012,000 885,000
Intangible assets 769,300,000 [1]   769,300,000 [1]   518,700,000                                           250,600,000 250,600,000 250,600,000 250,600,000
Goodwill 33,501,000 [1]   33,501,000 [1]   26,102,000                                           7,399,000 7,399,000 7,399,000 7,399,000
Other assets 14,858,000 [1]   14,858,000 [1]   17,182,000                                           76,000 76,000 76,000 76,000
Accounts payable 67,275,000 [1]   67,275,000 [1]   35,851,000                                           2,038,000 2,038,000 2,038,000 1,189,000
Accrued expenses and other current liabilities 141,167,000 [1]   141,167,000 [1]   134,414,000                                           967,000 967,000 967,000 1,504,000
Income taxes payable (Alios) 15,212,000 [1]   15,212,000 [1]                                               15,212,000 15,212,000 15,212,000  
Deferred tax liability, net 260,448,000 [1]   260,448,000 [1]   160,278,000                                           100,076,000 100,076,000 100,076,000 90,840,000
Other liabilities 6,233,000 [1]   6,233,000 [1]   2,265,000                                           3,188,000 3,188,000 3,188,000 3,191,000
Redeemable noncontrolling interest (Alios) 36,299,000 [1]   36,299,000 [1]                                               36,299,000 36,299,000 36,299,000 36,299,000
Noncontrolling interest (Alios) $ 105,332,000 [1]   $ 105,332,000 [1]                                               $ 105,332,000 $ 105,332,000 $ 105,332,000 $ 130,581,000
[1] Amounts include the assets and liabilities of Vertex's variable interest entity ("VIE"), Alios BioPharma, Inc. ("Alios"). Vertex's interests and obligations with respect to the VIE's assets and liabilities are limited to those accorded to Vertex in its agreement with Alios. See Note K to these condensed consolidated financial statements for amounts.